Key facts
- Francis Medical’s last known valuation is $230.0M (Dec 2024).
- It has raised $160.0M across 2 recorded rounds; the latest was Early Stage VC ($40.0M) in Dec 2024.
- Notable investors include Arboretum Ventures, Boston Scientific Ventures, CHK Cleveland Tonkawa, Coloplast, H2Oey Ventures — 8 tracked in total.
- Francis Medical has filed 2 Form Ds with the SEC since 2021, most recently Dec 2024 ($40.0M sold to 16 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Francis Medical
Funding rounds
2 roundsAbout Francis Medical
Developer of novel treatment devices designed to treat cancer in the prostate gland, urinary bladder, and kidney. The company's devices are based on water vapor technology that is being explored for treating a variety of endourological cancers using the energy stored in a few drops of water to ablate cancerous tissue, enabling medical professionals to not only treat cancerous tissue but also protect surrounding structures to reduce the likelihood of the life-altering side effects common with other treatments.
- Sector
- Healthcare
- HQ
- Maple Grove, MN, United States
- Founded
- 2018
- Employees
- 48
- Website
- francismedical.com/
- Ownership
- Privately Held (backing)
Francis Medical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Francis Medical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Francis Medical in its N-PORT filings yet. We sweep new filings monthly.